TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 84 filers reported holding TCR2 THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $233,086 | +403.0% | 155,390 | +234.9% | 0.00% | – |
Q4 2022 | $46,339 | -64.6% | 46,395 | -36.7% | 0.00% | – |
Q3 2022 | $131,000 | -69.8% | 73,248 | -51.0% | 0.00% | – |
Q2 2022 | $434,000 | -45.3% | 149,583 | -48.0% | 0.00% | – |
Q1 2022 | $794,000 | -62.0% | 287,402 | -35.9% | 0.00% | – |
Q4 2021 | $2,089,000 | +89.6% | 448,330 | +246.5% | 0.00% | – |
Q3 2021 | $1,102,000 | -57.1% | 129,377 | -17.4% | 0.00% | – |
Q2 2021 | $2,570,000 | +7687.9% | 156,580 | +10331.7% | 0.00% | – |
Q1 2021 | $33,000 | -95.0% | 1,501 | -93.0% | 0.00% | – |
Q4 2020 | $659,000 | +744.9% | 21,322 | +454.5% | 0.00% | – |
Q3 2020 | $78,000 | -96.4% | 3,845 | -97.3% | 0.00% | – |
Q2 2020 | $2,152,000 | +4204.0% | 140,114 | +2060.9% | 0.00% | – |
Q1 2020 | $50,000 | -84.2% | 6,484 | -70.8% | 0.00% | – |
Q4 2019 | $317,000 | +437.3% | 22,218 | +473.2% | 0.00% | – |
Q3 2019 | $59,000 | +5800.0% | 3,876 | +7213.2% | 0.00% | – |
Q2 2019 | $1,000 | -93.3% | 53 | -93.9% | 0.00% | – |
Q1 2019 | $15,000 | – | 872 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
MPM BioImpact LLC | 6,741,964 | $208,528,000 | 18.01% |
MPM ASSET MANAGEMENT LLC | 4,050,865 | $125,293,000 | 17.73% |
Consonance Capital Management LP | 584,885 | $71,268,000 | 6.66% |
SILVERARC CAPITAL MANAGEMENT, LLC | 136,000 | $4,206,000 | 2.44% |
Redmile Group, LLC | 2,832,888 | $87,621,000 | 1.06% |
Altium Capital Management LP | 73,991 | $2,289,000 | 0.86% |
PFM Health Sciences, LP | 775,794 | $23,995,000 | 0.84% |
Soleus Capital Management, L.P. | 199,867 | $6,182,000 | 0.82% |
MOODY ALDRICH PARTNERS LLC | 123,639 | $3,824,000 | 0.62% |
Sofinnova Investments, Inc. | 333,707 | $10,322,000 | 0.61% |